A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Advanced Solid TumorsHepatocellular Carcinoma

Interventions

DRUG

BBI503

DRUG

Sorafenib

Sorafenib 400mg twice daily (800mg total daily dose)

Trial Locations (1)

5 Sites, Chiba, Etc.

All Listed Sponsors

lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT02354898 - A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter